News and Media
Press Releases
Bloom Science to Present at the Biocom Global Partnering & Investor Conference
SAN DIEGO, Calif., February 20, 2024 — Bloom Science, Inc., today announced that Christopher Reyes, Ph.D., Chief Executive Officer of Bloom Science, will be presenting at the Biocom Global...
Bloom Science Granted Multiple New US and EU Patents Strengthening its IP Portfolio
SAN DIEGO, Calif., January 31, 2024 —Bloom Science, Inc., today announced that the United States Patent and Trademark Office (USPTO) and European Patent Office have issued multiple new patents, US...
Bloom Science to Present at the 7th Annual Sachs Neuroscience Innovation Forum
SAN DIEGO, Calif., January 2, 2024 - Bloom Science, Inc., today announced that Christopher Reyes, Ph.D., Chief Executive Officer of Bloom Science, will be presenting at the 7th Annual Sachs...
Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial of BL-001, a Potential First-in-Class Therapeutic Being Developed for Both Dravet Syndrome and ALS
BL-001 demonstrated a favorable safety and tolerability profile in healthy volunteers that supports dosing up to 10-fold higher than the efficacious dose level in animal models Dose dependent strain...
Bloom Science Names Top Biotechnology Executive, Dr. Grace E. Colón, Board Chair
SAN DIEGO, May 17, 2023 – Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis,...
Bloom Science Completes Enrollment in Phase 1 Trial of BL-001, a First-in-Class Therapy Being Developed for Dravet Syndrome
BL-001 Designed to Replicate the Antiepileptic Effects of the Ketogenic Diet Topline Results including Safety and Tolerability Expected in Third Quarter of 2023 SAN DIEGO, April 25, 2023 – Bloom...
Roya Hakimzadeh Joins Bloom Science as Director of Patient Advocacy
Bloom is excited to welcome Roya Hakimzadeh as Director of Patient Advocacy. Roya joins Bloom with nearly a decade of experience working in rare disease at companies spanning development of small...
Bloom Science Appoints Medicine Development Expert Dr. Stephen Wright to Clinical Advisory Board
SAN DIEGO, Calif., January 4, 2023 -- Dr. Stephen Wright joins Bloom Science, Inc., a clinical-stage biotechnology company developing novel medicines for neurological diseases and conditions, as a...
Bloom Science to Develop ALS Biotherapeutics with Exclusive Technology License from Yeda, the Technology Transfer Company of Weizmann Institute of Science
SAN DIEGO, Calif., January 4, 2023 -- Bloom Science, Inc., a clinical-stage biotechnology company developing novel medicines for neurological diseases and conditions, and Yeda Research and...
Bloom Science Completes Successful Pre-IND Meeting with the FDA for BL-001 Clinical Trial to Treat Dravet Syndrome
SAN DIEGO, Calif., January 4, 2023 -- Bloom Science, Inc., a clinical-stage biotechnology company developing novel medicines for neurological diseases and conditions, successfully completed a...
Bloom Science to Present Live at Biotech Showcase 2023
SAN DIEGO, Calif., December 17, 2022 -- Bloom Science, Inc. founder & CEO Christopher Reyes, PhD presents live at Biotech Showcase™ 2023 on Tuesday January 10 at 2:45 p.m. PT. Biotech Showcase,...
Harnessing the Gut–Immune–Brain Axis to Treat Disease
How a 100-year-old study spawned a novel class of multifunctional neurological treatments. Read the latest on Bloom Science's epilepsy and ALS lead programs and how a 100-year-old study spawned a...